摘要:
1,4-dihydropyridine derivatives and optically active 1,4-dihydropyridine derivatives with the following formula, having vasodilating activity based on calcium antagonism, and PAF antaognism, and methods of producing the same are disclosed: ##STR1## wherein (*) indicates a chiral center in the case of the optically active 1,4-dihydropyridine derivatives.
摘要:
A method of producing an aminobutene derivative of formula (I) by allowing a butenol derivative of formula (II) to react with an amide derivative of formula (III) is disclosed. The aminobutene derivative of formula (I) can be deprotected to produce an aminobutene derivative of formula (I-1) or an aminobutene derivative of formula (I-2): ##STR1## The aminobutene derivative of formula (I-A) can also be deprotected to produce the aminobutene derivative of formula (I-B). Any or all of the above aminobutene derivatives are useful as intermediates for producing anti-ulcer drugs, and anti-ulcer drugs having an inhibitory effect on gastric acid secretion based on the antagonism against histamine H.sub.2 receptor.
摘要:
Methods of producing carboxylic acid ester derivatives of formulae (I) and (II), which are useful, for instance, as intermediates for producing an anti-hypercholesterolemic agent having an inhibitory effect on HMG-CoA Reductase: ##STR1## wherein R.sup.1 and R.sup.2 are independently a protective group for hydroxyl group, or R.sup.1 and R.sup.2 integrally constitute a protective group for hydroxyl groups; R.sup.3 is an alkyl group, or an aryl group; and R.sup.4 is a substituted aryl group, a substituted heterocyclic group, a substituted vinyl group, or a substituted cycloalkenyl group; and ##STR2## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are respectively the same as defined in the above formula (I), are disclosed. In addition, intermediates for use in these methods of producing the carboxylic acid ester derivatives are disclosed.
摘要:
A 4-fluorobiphenyl derivative of formula (I), which is useful as a cholesterol lowering agent or a lipid lowering agent because of its strong inhibitory effect on HMG-CoA reductase), and which is also useful as an intermediate for producing the above-mentioned cholesterol lowering agent or lipid lowering agent: ##STR1## wherein A is a .omega.-oxycarbonyldihydroxybutyl group, a tetrahydropyranyl group, a .omega.-oxycarbonyl-3-oxobutyl group, a formyl group, or a cyano group; R.sup.1 is a halogen atom, an alkyl group, or a group represented by R.sup.5 O--, wherein R.sup.5 is a hydrogen atom, or an alkyl group; R.sup.2 is a hydrogen atom, an alkyl group; R.sup.3 is a hydrogen atom, or an alkyl group; R.sup.5 and R.sup.2 may form a five-membered ring or a six-membered ring in combination with the oxygen atoms to which R.sup.5 and R.sup.2 are respectively bonded, and R.sup.5 and R.sup.3 may form a five-membered ring or a six-membered ring in combination with the oxygen atom to which R.sup.5 is bonded.
摘要:
1,4-dihydropyridine derivatives and optically active 1,4-dihydropyridine derivatives with the following formula, having vasodilating activity based on calcium antagonism, and PAF antaognism, and methods of producing the same are disclosed: ##STR1## wherein (*) indicates a chiral center in the case of the optically active 1,4-dihydropyridine derivatives.
摘要:
1,4-Dihydropyridine derivatives of formula: ##STR1## wherein Ar.sup.1 represents an aromatic hydrocarbon group or an aromatic heteromonocyclic or heterobicyclic group containing therein 1 to 3 atoms selected from the group consisting of oxygen, sulfur and nitrogen; R.sup.1 represents a hydrocarbon group which may have one or more substituents; A represents (i) a straight chain or branched chain unsaturated hydrocarbon group, (ii) a cyclic unsaturated hydrocarbon group, or (iii) a group selected from the group consisting of --R--O--N.dbd.CH--, --R--N.dbd.N--, --R--CH.dbd.N-- and --R--N.dbd.CH--, in which R is an alkylene group having 1 to 6 carbon atoms; B represents an alkylene or alkenylene group having 1 to 3 carbon atoms, which may have a substituent; Ar.sup.2 represents an aromatic hydrocarbon group or a heterocyclic group; Ar.sup.3 represents a heterocyclic group which may have one or more substituents; and n is 0 or 1, and the corresponding optical active 1,4-dihydropyridine derivatives, having an optically active cite as indicated by *, have both superior vasodilative and platelet aggregation inhibiting activities.
摘要翻译:其中Ar 1表示芳族烃基或含有选自氧,硫和氮的1至3个原子的芳族杂单环或杂双环基; R1表示可具有一个或多个取代基的烃基; A表示(i)直链或支链不饱和烃基,(ii)环状不饱和烃基,或(iii)选自-RON = CH-,-RN = N-,-R -CH = N-和-RN = CH-,其中R是具有1至6个碳原子的亚烷基; B表示可以具有取代基的碳原子数1〜3的亚烷基或亚烯基; Ar 2表示芳香族烃基或杂环基; Ar 3表示可以具有一个以上取代基的杂环基; 并且n为0或1,并且具有如*所示的光学活性引物的相应的光学活性1,4-二氢吡啶衍生物具有优异的血管扩张和血小板聚集抑制活性。
摘要:
A method of producing a 2-naphthamide derivative of formula (I) that can be employed as an antiallergic agent or an agent for curing allergosis, and compounds for producing the 2-naphthamide derivative are provided: ##STR1## wherein R.sup.1 and R.sup.2 are each independently an unsubstituted or substituted aromatic hydrocarbon group, or an unsubstituted or substituted aromatic heterocyclic group; R.sup.3 is an acyl group, an alkoxylcarbonyl group, a substituted carbamoyl group, or an unsubstituted or substituted alkyl group.
摘要:
1,4-dihydropyridine derivatives of formula (I): ##STR1## wherein Ar.sup.1 and Ar.sup.2 each represent an unsubstituted or substituted aromatic hydrocarbon or aromatic heterocyclic group; and R.sup.1 represents --CO.sub.2 R.sup.2, --SO.sub.2 R.sup.3, --COR.sup.4, --CON(R.sup.5).sub.2, --CH--or --NO.sub.2 in which R.sup.2 is hydrogen, a straight chain, branched chain or cyclic saturated hydrocarbon group, which may have a substituent or a straight chain, branched chain or cyclic unsaturated hydrocarbon group having 2 to 10 carbon atoms, which may have a substituent, R.sup.3 is an alkyl group having 1 to 4 carbon atoms, R.sup.4 is an alkyl group having 1 to 4 carbon atoms or a phenyl group; and R.sup.5 is an alkyl group having 1 to 4 carbon atoms.
摘要翻译:式(I)的1,4-二氢吡啶衍生物:其中Ar 1和Ar 2各自表示未取代或取代的芳族烃或芳族杂环基; 和R 1表示可以具有取代基的直链,支链或环状饱和烃基的-CO 2 R 2,-SO 2 R 3,-COR 4,-CON(R 5)2,-CH或-NO 2, 可以具有取代基的碳原子数为2〜10的直链,支链或支链或环状不饱和烃基,R3为碳原子数1〜4的烷基,R4为碳原子数1〜4的烷基或苯基 ; R5为碳原子数为1〜4的烷基。
摘要:
A pyrimidine nucleus-containing compound represented by the formula (I): wherein ring A represents the ring of the formula (a): in which R1 is a nitro group, an amino group, a substituted amino group or a halogen atom, or the ring of the formula (b): in which R1′ is the group such as an alkyl group or an alkenyl group; R2 to R5 independently represent the group such as an alkyl group or an alkenyl group; with the proviso that at least one of R2 to R5 is an alkenyl group, or acid addition salts thereof.
摘要:
1,4-dihydropyridine derivatives and optically active 1,4-dihydropyridine derivatives with the following formula, having vasodilating activity based on calcium antagonism, and PAF antaognism, and methods of producing the same are disclosed: ##STR1## wherein (*) indicates a chiral center in the case of the optically active 1,4-dihydropyridine derivatives.